uu.seUppsala University Publications
Change search
ReferencesLink to record
Permanent link

Direct link
Lung cancer following chemotherapy and radiotherapy for Hodgkin's disease
National Cancer Institute, USA.
National Cancer Institute, USA.
Show others and affiliations
2002 (English)In: Journal of the National Cancer Institute, ISSN 0027-8874, E-ISSN 1460-2105, Vol. 94, no 3, 182-192 p.Article in journal (Refereed) Published
Abstract [en]

BACKGROUND: Lung cancer is a frequent cause of death in patients cured of Hodgkin's disease, but the contributions of chemotherapy, radiotherapy, and smoking are not well described. We quantified the risk of treatment-associated lung cancer, taking into account tobacco use.

METHODS: Within a population-based cohort of 19 046 Hodgkin's disease patients (diagnosed from 1965 through 1994), a case-control study of lung cancer was conducted. The cumulative amount of cytotoxic drugs, the radiation dose to the specific location in the lung where cancer developed, and tobacco use were compared for 222 patients who developed lung cancer and for 444 matched control patients. All statistical tests were two-sided.

RESULTS: Treatment with alkylating agents without radiotherapy was associated with increased lung cancer risk (relative risk [RR] = 4.2; 95% confidence interval [CI] = 2.1 to 8.8), as was radiation dose of 5 Gy or more without alkylating agents (RR = 5.9; 95% CI = 2.7 to 13.5). Risk increased with both increasing number of cycles of alkylating agents and increasing radiation dose (P for trend <.001). Among patients treated with mechlorethamine, vincristine, procarbazine, and prednisone (MOPP), risk increased with cumulative amounts of mechlorethamine and procarbazine (P<.001) when evaluated separately. Statistically significantly elevated risks of lung cancer were apparent within 1-4 years after treatment with alkylating agents, whereas excess risk after radiotherapy began 5 years after treatment and persisted for more than 20 years. Risk after treatment with alkylating agents and radiotherapy together was as expected if individual excess risks were summed. Tobacco use increased lung cancer risk more than 20-fold; risks from smoking appeared to multiply risks from treatment.

CONCLUSIONS: Past treatments with alkylating agents and radiation therapy for Hodgkin's disease were associated with an increased risk of lung cancer in a dose-dependent and additive fashion. The precise risk estimates, however, should be interpreted cautiously, given the possible residual and enhancing effects of tobacco.

Place, publisher, year, edition, pages
2002. Vol. 94, no 3, 182-192 p.
National Category
Cancer and Oncology
URN: urn:nbn:se:uu:diva-222094PubMedID: 11830608OAI: oai:DiVA.org:uu-222094DiVA: diva2:710707
Available from: 2014-04-08 Created: 2014-04-08 Last updated: 2014-04-09Bibliographically approved

Open Access in DiVA

No full text


Search in DiVA

By author/editor
Glimelius, BengtGlimelius, Ingrid
By organisation
OncologyDepartment of Radiology, Oncology and Radiation Science
In the same journal
Journal of the National Cancer Institute
Cancer and Oncology

Search outside of DiVA

GoogleGoogle Scholar
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

Altmetric score

Total: 181 hits
ReferencesLink to record
Permanent link

Direct link